Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Marc Treluyer

Showing results (81-90 of 171) with videos related to

Pageof 18
Sort By:
Cardiovascular Drugs and Therapy|February 17, 2021
Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19Laurent Chouchana, Nathanaël Beeker, Nicolas Garcelon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavirConstance Delaugerre, Jean-Paul Teglas, Jean-Marc Treluyer, et al.
British Journal of Clinical Pharmacology|July 22, 2014
Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?Floris Fauchet, Jean-Marc Treluyer, Elodie Valade, et al.
Autoimmunity Reviews|November 16, 2020
Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approachCamille Rasmussen, Mylène Tisseyre, Julie Garon-Czmil, et al.
AIDS (London, England)|November 1, 2021
High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapyClaire Pressiat, Thomas d'Aquin Toni, Jean-Marc Treluyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
European Journal of Clinical Pharmacology|September 1, 2012
Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approachSihem Benaboud, Saïk Urien, Eric Thervet, et al.
The Journal of Antimicrobial Chemotherapy|June 4, 2018
Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infectionNadège Neant, Roman Klifa, Naïm Bouazza, et al.
Therapeutic Drug Monitoring|January 15, 2011
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavirTim R Cressey, Saik Urien, Deborah Hirt, et al.
Pageof 18

Showing results (81-90 of 171) with videos related to

Sort By:
Pageof 18
Cardiovascular Drugs and Therapy|February 17, 2021
Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19Laurent Chouchana, Nathanaël Beeker, Nicolas Garcelon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavirConstance Delaugerre, Jean-Paul Teglas, Jean-Marc Treluyer, et al.
British Journal of Clinical Pharmacology|July 22, 2014
Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?Floris Fauchet, Jean-Marc Treluyer, Elodie Valade, et al.
Autoimmunity Reviews|November 16, 2020
Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approachCamille Rasmussen, Mylène Tisseyre, Julie Garon-Czmil, et al.
AIDS (London, England)|November 1, 2021
High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapyClaire Pressiat, Thomas d'Aquin Toni, Jean-Marc Treluyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
European Journal of Clinical Pharmacology|September 1, 2012
Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approachSihem Benaboud, Saïk Urien, Eric Thervet, et al.
The Journal of Antimicrobial Chemotherapy|June 4, 2018
Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infectionNadège Neant, Roman Klifa, Naïm Bouazza, et al.
Therapeutic Drug Monitoring|January 15, 2011
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavirTim R Cressey, Saik Urien, Deborah Hirt, et al.
Pageof 18